Sustained-Release Steroids for the Treatment of Diabetic Macular Edema

Current Diabetes Reports

Volumn 15, Issue 11, 2015, Pages

  Daruich, Alejandra ^a   Matet, Alexandre ^a   Behar Cohen, Francine ^a,b,c  

^a JULES GONIN EYE HOSPITAL   (Switzerland)

^b CENTRE DE RECHERCHE DES CORDELIERS   (France)

^c UNIVERSITÉ PARIS DESCARTES   (France)

Author keywords

Delayed action preparations; Dexamethasone; Diabetes mellitus; Fluocinolone acetonide; Glucocorticoids; Macular edema; Therapy

Indexed keywords

BEVACIZUMAB; CORTICOSTEROID; DEXAMETHASONE; FLUOCINOLONE ACETONIDE; RANIBIZUMAB; TRIAMCINOLONE ACETONIDE; DELAYED RELEASE FORMULATION; GLUCOCORTICOID; STEROID;

CATARACT; DEXAMETHASONE INTRAVITREAL IMPLANT; DIABETIC MACULAR EDEMA; DRUG DELIVERY DEVICE; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG FORMULATION; HUMAN; INTRAOCULAR HYPERTENSION; INTRAOCULAR PRESSURE; MONOTHERAPY; NONHUMAN; OUTCOME ASSESSMENT; PHASE 3 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SUSTAINED DELIVERY FLUOCINOLONE ACETONIDE INSERT; SUSTAINED DRUG RELEASE; VISUAL ACUITY; ANIMAL; CLINICAL TRIAL (TOPIC); DELAYED RELEASE FORMULATION; DIABETES COMPLICATIONS; MACULAR EDEMA; METABOLISM; TREATMENT OUTCOME;

ANIMALS; CLINICAL TRIALS AS TOPIC; DELAYED-ACTION PREPARATIONS; DIABETES COMPLICATIONS; GLUCOCORTICOIDS; HUMANS; MACULAR EDEMA; STEROIDS; TREATMENT OUTCOME;

EID: 84942426227     PISSN: 15344827     EISSN: 15390829     Source Type: Journal    
DOI: 10.1007/s11892-015-0669-3     Document Type: Review

References (45)

1. Kwon S, Hermayer KL. Glucocorticoid-induced hyperglycemia. Am J Med Sci. 2013;345:274–7.
2. Perez A, Jansen-Chaparro S, Saigi I, Bernal-Lopez MR, Miñambres I, Gomez-Huelgas R. Glucocorticoid-induced hyperglycemia. J Diabetes. 2014;6:9–20.
3. Rafacho A, Ortsäter H, Nadal A, Quesada I. Glucocorticoid treatment and endocrine pancreas function: implications for glucose homeostasis, insulin resistance and diabetes. J Endocrinol. 2014;223:R49–62.
4. Rojas J, Chávez-Castillo M, Chávez-Castillo M, Cabrera M, Cabrera M, Bermúdez V, et al. Glucocorticoid-induced death of pancreatic Beta cells: an organized chaos. JOP. 2015;16:11–9.
5. Hawkins UA, Gomez-Sanchez EP, Gomez-Sanchez CM, Gomez-Sanchez CE. The ubiquitous mineralocorticoid receptor: clinical implications. Curr Hypertens Rep. 2012;14:573–80.
6. Hunter RW, Bailey MA. Glucocorticoids and 11β-hydroxysteroid dehydrogenases: mechanisms for hypertension. Curr Opin Pharmacol. 2015;21:105–14.
7. Frey FJ, Odermatt A, Frey BM. Glucocorticoid-mediated mineralocorticoid receptor activation and hypertension. Curr Opin Nephrol Hypertens. 2004;13:451–8.
8. Goodwin JE, Geller DS. Glucocorticoid-induced hypertension. Pediatr Nephrol. 2012;27:1059–66.
9. Fardet L, Fève B. Systemic glucocorticoid therapy: a review of its metabolic and cardiovascular adverse events. Drugs. 2014;74:1731–45.
10. Stewart MW. Corticosteroid use for diabetic macular edema: old fad or new trend? Curr Diab Rep. 2012;12:364–75.
11. Duh EJ. A novel mechanism for glucocorticoid-induced tightening of endothelial barriers. Invest Ophthalmol Vis Sci. 2013;54:4016.
12. Keil JM, Liu X, Antonetti DA. Glucocorticoid induction of occludin expression and endothelial barrier requires transcription factor p54 NONO. Invest Ophthalmol Vis Sci. 2013;54:4007–15.
13. Zhao M, Bousquet E, Valamanesh F, Farman N, Jeanny J-C, Jaisser F, et al. Differential regulations of AQP4 and Kir4.1 by triamcinolone acetonide and dexamethasone in the healthy and inflamed retina. Invest Ophthalmol Vis Sci. 2011;52:6340–7.
14. Jonas JB, Söfker A. Intraocular injection of crystalline cortisone as adjunctive treatment of diabetic macular edema. Am J Ophthalmol. 2001;132:425–7.
15. Martidis A, Duker JS, Greenberg PB, Rogers AH, Puliafito CA, Reichel E, et al. Intravitreal triamcinolone for refractory diabetic macular edema. Ophthalmology. 2002;109:920–7.
16. Torriglia A, Valamanesh F, Behar-Cohen F. On the retinal toxicity of intraocular glucocorticoids. Biochem Pharmacol. 2010;80:1878–86.
17. El Zaoui I, Behar-Cohen F, Torriglia A. Glucocorticoids exert direct toxicity on microvasculature: analysis of cell death mechanisms. Toxicol Sci. 2015;143:441–53.
18. Schulze-Döbold C, Weber M. Loss of visual function after repeated intravitreal injections of triamcinolone acetonide in refractory uveitic macular oedema. Int Ophthalmol. 2009;29:427–9.
19. Doshi A, Gariano RF. Visual loss associated with accidental subretinal injection of triamcinolone acetonide. Retin Cases Brief Rep. 2008;2:160–2.
20. Jaissle GB, Bartz-Schmidt KU, Szurman P. Optic atrophy subsequent to epiretinal triamcinolone deposits in an eye following inner limiting membrane peeling. Ophthalmologe. 2008;105:575–7.
21. Chang-Lin J-E, Attar M, Acheampong AA, Robinson MR, Whitcup SM, Kuppermann BD, et al. Pharmacokinetics and pharmacodynamics of a sustained-release dexamethasone intravitreal implant. Invest Ophthalmol Vis Sci. 2011;52:80–6.
22. Gillies MC, Lim LL, Campain A, Quin GJ, Salem W, Li J, et al. A randomized clinical trial of intravitreal bevacizumab versus intravitreal dexamethasone for diabetic macular edema: the BEVORDEX study. Ophthalmology. 2014;121:2473–81. This randomized trial demonstrates the injection-sparing benefit of long-lasting steroids compared to a.
23. Campochiaro PA, Nguyen QD, Hafiz G, Bloom S, Brown DM, Busquets M, et al. Aqueous levels of fluocinolone acetonide after administration of fluocinolone acetonide inserts or fluocinolone acetonide implants. Ophthalmology. 2013;120:583–7.
24. Campochiaro PA, Brown DM, Pearson A, Chen S, Boyer D, Ruiz-Moreno J, et al. Sustained delivery fluocinolone acetonide vitreous inserts provide benefit for at least 3 years in patients with diabetic macular edema. Ophthalmology. 2012;119:2125–32. This randomized trial presents encouraging long-term results for the fluocinolone acetonide insert.
25. Photocoagulation for diabetic macular edema. Early Treatment Diabetic Retinopathy Study report number 1. Early Treatment Diabetic Retinopathy Study research group. Arch. Ophthalmol. 1985;103:1796–806.
26. Diabetic Retinopathy Clinical Research Network. A randomized trial comparing intravitreal triamcinolone acetonide and focal/grid photocoagulation for diabetic macular edema. Ophthalmology. 2008;115:1447–9. 1449.e1–10.
27. Gillies MC, Sutter FKP, Simpson JM, Larsson J, Ali H, Zhu M. Intravitreal triamcinolone for refractory diabetic macular edema: two-year results of a double-masked, placebo-controlled, randomized clinical trial. Ophthalmology. 2006;113:1533–8.
28. Gillies MC, Simpson JM, Gaston C, Hunt G, Ali H, Zhu M, et al. Five-year results of a randomized trial with open-label extension of triamcinolone acetonide for refractory diabetic macular edema. Ophthalmology. 2009;116:2182–7.
29. Gunther J, Ip M. Intravitreal steroid versus macular laser for treatment of diabetic macular edema. Curr Diab Rep. 2009;9:272–6.
30. Nguyen QD, Brown DM, Marcus DM, Boyer DS, Patel S, Feiner L, et al. Ranibizumab for diabetic macular edema: results from 2 phase III randomized trials: RISE and RIDE. Ophthalmology. 2012;119:789–801.
31. Brown DM, Nguyen QD, Marcus DM, Boyer DS, Patel S, Feiner L, et al. Long-term outcomes of ranibizumab therapy for diabetic macular edema: the 36-month results from two phase III trials: RISE and RIDE. Ophthalmology. 2013;120:2013–22. Large-scale clinical trial demonstrating the superiority of the anti-VEGF ranibizumab over placebo in diabetic macular edema.
32. Elman MJ, Bressler NM, Qin H, Beck RW, Ferris FL, Friedman SM, et al. Expanded 2-year follow-up of ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema. Ophthalmology. 2011;118:609–14.
33. Boyer DS, Yoon YH, Belfort R, Bandello F, Maturi RK, Augustin AJ, et al. Three-year, randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with diabetic macular edema. Ophthalmology. 2014;121:1904–14. Large randomized trial demonstrating the superiority of sustained-release intravitreal dexamethasone over placebo for macular edema.
34. Callanan DG, Gupta S, Boyer DS, Ciulla TA, Singer MA, Kuppermann BD, et al. Dexamethasone intravitreal implant in combination with laser photocoagulation for the treatment of diffuse diabetic macular edema. Ophthalmology. 2013;120:1843–51.
35. Maturi RK, Bleau L, Saunders J, Mubasher M, Stewart MW. (2015) A 12-month, single-masked, randomized controlled study of eyes with persistent diabetic macular edema after multiple anti-VEGF injections to assess the efficacy of the dexamethasone-delayed delivery system as an adjunct to bevacizumab compared with continued bevacizumab monotherapy. Retina.
36. Boyer DS, Faber D, Gupta S, Patel SS, Tabandeh H, Li X-Y, et al. Dexamethasone intravitreal implant for treatment of diabetic macular edema in vitrectomized patients. Retina. 2011;31:915–23.
37. Medeiros MD, Alkabes M, Navarro R, Garcia-Arumí J, Mateo C, Corcóstegui B. Dexamethasone intravitreal implant in vitrectomized versus nonvitrectomized eyes for treatment of patients with persistent diabetic macular edema. J Ocul Pharmacol Ther. 2014;30:709–16.
38. Cunha-Vaz J, Ashton P, Iezzi R, Campochiaro P, Dugel PU, Holz FG, et al. Sustained delivery fluocinolone acetonide vitreous implants: long-term benefit in patients with chronic diabetic macular edema. Ophthalmology. 2014;121:1892–903. Post hoc study showing a greater benefit of fluocinolone acetonide insert in patient with chronic, refractory diabetic macular edema of 3 years duration or more.
39. Ciulla TA, Harris A, McIntyre N, Jonescu-Cuypers C. Treatment of diabetic macular edema with sustained-release glucocorticoids: intravitreal triamcinolone acetonide, dexamethasone implant, and fluocinolone acetonide implant. Expert Opin Pharmacother. 2014;15:953–9.
40. James ER. The etiology of steroid cataract. J Ocul Pharmacol Ther. 2007;23:403–20.
41. Stokes J, Noble J, Brett L, Phillips C, Seckl JR, O’Brien C, et al. Distribution of glucocorticoid and mineralocorticoid receptors and 11beta-hydroxysteroid dehydrogenases in human and rat ocular tissues. Invest Ophthalmol Vis Sci. 2000;41:1629–38.
42. Jobling AI, Augusteyn RC. What causes steroid cataracts? A review of steroid-induced posterior subcapsular cataracts. Clin Exp Optom. 2002;85:61–75.
43. Jones R, Rhee DJ. Corticosteroid-induced ocular hypertension and glaucoma: a brief review and update of the literature. Curr Opin Ophthalmol. 2006;17:163–7.
44. Zhao M, Valamanesh F, Celerier I, Savoldelli M, Jonet L, Jeanny J-C, et al. The neuroretina is a novel mineralocorticoid target: aldosterone up-regulates ion and water channels in Müller glial cells. FASEB J. 2010;24:3405–15.
45. Bousquet E, Zhao M, Ly A, Leroux Les Jardins G, Goldenberg B, Naud M-C, et al. The aldosterone-mineralocorticoid receptor pathway exerts anti-inflammatory effects in endotoxin-induced uveitis. PLoS One. 2012;7, e49036.